CD63 as a potential biomarker for patients with ovarian cancer
- 7 January 2025
- journal article
- research article
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 306, 87-93
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (22K16836)
This publication has 29 references indexed in Scilit:
- Sensitive phenotyping of serum extracellular vesicles on a SERS-microfluidic platform for early-stage clinical diagnosis of ovarian carcinomaBiosensors and Bioelectronics, 2024
- Functional enhancement of exosomes derived from NK cells by IL-15 and IL-21 synergy against hepatocellular carcinoma cells: The cytotoxicity and apoptosis in vitro studyHeliyon, 2023
- CD63 acts as a functional marker in maintaining hematopoietic stem cell quiescence through supporting TGFβ signaling in miceCell Death & Differentiation, 2021
- High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironmentCell Reports, 2021
- Communication by Extracellular Vesicles: Where We Are and Where We Need to GoCell, 2016
- Diagnosis by extracellular vesiclesNature, 2015
- Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein AggregatesPharmaceutical Research, 2010
- Lateral organization of membrane proteins: tetraspanins spin their webBiochemical Journal, 2009
- Tetraspanin functions and associated microdomainsNature Reviews Molecular Cell Biology, 2005
- Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinaseBiochemical Journal, 2000